NCT00292071View on ClinicalTrials.gov

Open, Pharmacokinetic Study of Caspofungin Acetate in Immunocompromised Young Children With Febrile Neutropenia (0991-042)

PHASE2CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

May 31, 2004

Primary Completion Date

July 31, 2006

Study Completion Date

July 31, 2006

Conditions
Fungal Infection
Interventions
DRUG

caspofungin acetate

(50 mg/m²/day and 70 mg/m²/day) Caspofungin will be given for a minimum of 4 days (or at least 2 separate days of 7-point plasma sampling). Patients will be administered caspofungin for a maximum of 28 days.

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00292071 - Open, Pharmacokinetic Study of Caspofungin Acetate in Immunocompromised Young Children With Febrile Neutropenia (0991-042) | Biotech Hunter | Biotech Hunter